Mergers, split-off, purchases, and sales... Global biopharmaceutical companies are busy making transformations to their respective businesses.

Among the various transformations being made, the spin-offs and sales of the multinational pharmaceutical companies’ divisions have received particular attention over the past few years. Although such transformations are made under the premise of adopting a "selection and concentration" strategy, the spin-offs and sales draw out various positive and negative responses from society. One thing to note is that this phenomenon is being serially observed in various

Novartis, one of the leading Big Pharmas, is currently integrating and spinning off its